ArteraAI Announces Research Agreement with CorePlus

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic…
Click here to view original post

Advertisement — Advertise with Biotech Networks